Business
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2024. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the f
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"Basilea Pharmaceutica AG, Allschwil","displaySize":"","headline":null,"caption":"Basilea Pharmaceutica AG, Allschwil","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/863aV4U6H3aPDpGW_iaFpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7","width":300,"height":102}},"lazy":false},{"type":"text","content":"Allschwil, Switzerland, April 16, 2025","length":38,"tagName":"p"},{"type":"text","content":"Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2024.","length":327,"tagName":"p"},{"type":"text","content":"At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2024. They also endorsed carrying forward the accumulated deficit and approved the discharge of the members of the board of directors and the management committee.","length":310,"tagName":"p"},{"type":"text","content":"Mr. Stephan Schindler was elected as chairman and Mr. Leonard Kruimer, Dr. Martin Nicklasson, Dr. Nicole Onetto, Dr. Carole Sable and Dr. Thomas Werner were re-elected as members of the board of directors. In addition, Mr. Kruimer was elected, and Dr. Nicklasson and Dr. Onetto were re-elected to the compensation committee. The term of all board members lasts until the AGM 2026.","length":390,"tagName":"p"},{"type":"text","content":"The shareholders also approved the proposed maximum aggregate amount of compensation for the board of directors for the period from the AGM 2025 to the AGM 2026, and the maximum aggregate amount of total compensation (fixed and variable) for the management committee for the financial year 2026. In a non-binding advisory vote, the shareholders endorsed the compensation report for the financial year 2024.","length":406,"tagName":"p"},{"type":"text","content":"Finally, the shareholders re-elected Dr. Caroline Cro...